IDEAYA Biosciences, Inc.
IDYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.82 | 0.11 | -0.03 |
| FCF Yield | 5.83% | -3.40% | -4.26% | -5.47% |
| EV / EBITDA | 18.02 | -23.23 | -18.91 | -16.81 |
| Quality | ||||
| ROIC | 9.67% | -9.00% | -8.04% | -13.37% |
| Gross Margin | 99.50% | 0.00% | 0.00% | 90.81% |
| Cash Conversion Ratio | 1.19 | 0.81 | 0.84 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 109.14% | -46.28% | -47.16% | -48.39% |
| Free Cash Flow Growth | 325.18% | -2.38% | 49.76% | -147.04% |
| Safety | ||||
| Net Debt / EBITDA | -2.26 | 1.15 | 1.46 | 0.50 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,610.65 | -1,260.58 | -1,400.52 | -2,158.42 |